The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards RVPH. This endorsement reaffirms the firm's confidence in Reviva Pharmaceuticals' potential, likely leading to increased investor interest and potentially a positive impact on the stock's short-term price movement.